Updated:
Taysha Gene Therapies
Taysha Gene Therapies: a publicly traded biotech founded by RA Session II, advancing an AAV gene therapy pipeline for rare CNS diseases out of UT...
Taysha Gene Therapies
Taysha Gene Therapies launched in 2020 when founder and President RA Session II secured an exclusive option to license a portfolio of AAV gene therapies developed at UT Southwestern Medical Center. Backed by a $30 million seed financing, the company went public on the Nasdaq the same year, raising $157 million in its IPO (per the firm's SEC filings, 2020). The founding thesis was unusual: consolidate a sweeping package of preclinical programs under one publicly traded vehicle and advance multiple CNS and neurodegenerative disease candidates simultaneously. The company's pipeline is concentrated on central nervous system disorders, with gene therapy candidates targeting giant axonal neuropathy (GAN), Rett syndrome, and SURF1-associated Leigh syndrome. Its lead clinical asset, TSHA-102 for Rett syndrome, uses a novel miRNA-responsive auto-regulatory element to control transgene expression. Taysha has also secured a worldwide exclusive license from UTSW for a second-generation GAN gene therapy, which is in development. Direct manufacturing capability is handled through a partnership with Catalent, a key component for scalability in this space. Headquartered in Dallas, Texas, Taysha operates with a lean corporate structure typical of clinical-stage biotechs. Sean P. Nolan serves as CEO, having taken over from RA Session II in a planned leadership transition in 2022 (per the firm, 2022). In November 2023, the company raised $257 million in a private placement led by RA Capital Management, extending its cash runway into 2027 (per Fierce Biotech, November 2023). The firm also engaged in a 1-for-14 reverse stock split in 2023 to regain Nasdaq listing compliance, signaling the operational recalibration underway. Taysha's structural differentiator lies in its licensing model—rather than building a platform in-house, it acquired an entire portfolio of gene therapies from a single academic institution and advanced them simultaneously as a public company. This 'hub-and-spoke' approach to clinical development, combined with fast-follower pivotal trial designs, sets it apart from peers that typically build more slowly around a single asset. The company's partnership with leading academic centers remains central to its sourcing strategy.
General information
Firm type
Asset Manager
Year founded
2020
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Dallas
Corporate office
Dallas, TX, United States
Principals
Sean P. Nolan
Chief Executive Officer
RA Session II
President, Founder
Sector focus
Frequently asked questions
What is Taysha Gene Therapies' lead clinical candidate?
TSHA-102 is the company's lead candidate, currently in early clinical trials for Rett syndrome. It uses a novel miRNA-responsive auto-regulatory element designed to control transgene expression. The program is the primary focus of current research and development spending.
How did Taysha Gene Therapies originate?
The company was formed in 2020 through an exclusive option agreement with UT Southwestern Medical Center, which provided access to a broad portfolio of AAV gene therapy programs. This allowed Taysha to launch as a multi-asset public company rather than building a pipeline from a single asset.
What is Taysha's manufacturing strategy for gene therapies?
Taysha has partnered with Catalent for manufacturing support, a common approach for clinical-stage biotechs in gene therapy. The company does not operate its own large-scale production facilities, relying on contract development and manufacturing organizations for clinical and potential commercial supply.
How does Taysha Gene Therapies fit into the public biotech landscape?
Taysha is a clinical-stage, publicly traded gene therapy company listed on the Nasdaq. Its focus on rare CNS diseases places it alongside peers like Sarepta Therapeutics and PTC Therapeutics, though its platform-driven approach—licensing multiple programs from an academic institution—is distinct from single-asset focused startups.
What is the significance of Taysha's reverse stock split in 2023?
In 2023, Taysha implemented a 1-for-14 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, a common regulatory step for clinical-stage biotechs after periods of declining share price. The move is operational and does not alter the company's underlying pipeline or strategy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: